# Complement Factor B (CFB): Complete Research Profile — Alternative Pathway C3 Convertase Assembly, Gain-of-Function Variants, and Complement Therapeutics Research (2026)
Research Use Only. The content below is intended for laboratory and academic research purposes. It does not describe or endorse human or animal use, dosing, or clinical protocols.
Complement Factor B (CFB) is the catalytic engine of the alternative complement pathway — the serine protease zymogen that, once proteolytically activated, associates with surface-bound C3b to form the C3bBb convertase responsible for alternative-pathway amplification. While Complement Factor H is the primary brake on this amplification loop, Factor B is its counterpart: the accelerator. Together, Factor B and Factor H define the equilibrium between complement amplification and host self-protection that, when disrupted, underlies diseases ranging from C3 glomerulopathy to paroxysmal nocturnal hemoglobinuria (PNH).
Understanding Factor B is also increasingly important for complement therapeutics research: iptacopan, the first oral Factor B inhibitor, received FDA approval for PNH in December 2023, and danicopan, an oral Factor D inhibitor that acts immediately upstream of Factor B, received approval as add-on therapy for extravascular hemolysis in the same patient population. Factor B is among the most pharmacologically tractable nodes in the complement cascade.
What Is Complement Factor B?
Complement Factor B (gene symbol CFB, chromosome 6p21.33 within the major histocompatibility complex class III region) is a single-chain, ~93 kDa plasma glycoprotein synthesized primarily by the liver and circulating in plasma at a concentration of approximately 180–200 µg/mL. It is homologous to complement C2, the equivalent proenzyme in the classical/lectin pathways — the two proteins are the functional counterparts in their respective arms of the complement cascade.
Like C2, Factor B is a zymogen: it circulates in an inactive form and requires proteolytic processing to generate enzymatic activity. This processing is carried out by complement Factor D, a constitutively active serine protease that cleaves Factor B only when Factor B is appropriately positioned — bound to the activating surface via C3b.
Structure: Five Domains Arranged Across Two Functional Fragments
Crystal structural analysis of full-length Factor B at 2.3 Å resolution revealed a five-domain architecture organized into two major fragments defined by the Factor D cleavage site (Milder et al., 2007, Nat Struct Mol Biol, PMID: 17310251):
Ba fragment (~33 kDa) — the N-terminal fragment released upon Factor D cleavage, comprising three complement control protein (CCP) domains (CCP1–3). The Ba fragment itself has reported biological activity beyond being a simple "discarded" activation product: it binds properdin and has been reported to suppress B-cell proliferation in certain experimental contexts, though its primary role in the alternative-pathway mechanism is providing the N-terminal architecture that keeps the full-length zymogen inactive.
Bb fragment (~60 kDa) — the C-terminal catalytic fragment that remains associated with C3b after Ba release, comprising:
- •Von Willebrand factor type A (vWFA) domain — contains a metal ion-dependent adhesion site (MIDAS motif) that binds Mg²⁺ and through this divalent-cation-dependent interaction engages C3b. This domain is structurally and mechanistically homologous to the I-domains of integrins.
- •Serine protease (SP) domain — the trypsin-family catalytic domain that cleaves C3 into C3a and C3b, driving the amplification loop.
A key insight from the crystal structure is that in the native zymogen, the canonical activation helix of the vWFA domain is displaced from its active position by a helix from the domain linker, and the scissile-bond arginine that Factor D must cleave is sequestered near the vWFA–SP domain interface. C3b binding drives conformational rearrangements that displace the N-terminal CCP domains, reposition the two central helices, and expose the scissile bond — elegantly coupling C3b recognition with productive Factor D accessibility.
The C3bBb Convertase: Assembly, Function, and Properdin Stabilization
The critical structural biology context for how Factor B activates was further established by co-crystal structures of the proconvertase C3bB complex and the ternary C3bB·Factor D complex, revealing at atomic resolution how C3b-bound Factor B presents its scissile Arg234–Lys235 bond to Factor D (Forneris et al., 2010, Science, PMID: 21205667).
The assembly and activation sequence proceeds through well-characterized steps:
1. Tick-over — Spontaneous, low-level hydrolytic opening of C3's internal thioester generates fluid-phase C3(H₂O), which loosely resembles C3b and can associate with Factor B to form a fluid-phase initiation complex C3(H₂O)B. Factor D cleaves this to generate a fluid-phase C3 convertase C3(H₂O)Bb, which deposits small amounts of C3b on nearby surfaces.
2. Surface deposition and proconvertase assembly — C3b covalently attaches to hydroxyl or amine groups on surface targets via its newly exposed thioester. Surface-bound C3b recruits native Factor B to form the proconvertase C3bB, a Mg²⁺-dependent complex.
3. Factor D cleavage and convertase activation — Factor D, a constitutively active serine protease that is specific for surface-bound Factor B (it cannot cleave free Factor B efficiently), cleaves C3bB at the Arg234–Lys235 bond, releasing Ba and generating the active convertase C3bBb.
4. Amplification — C3bBb cleaves soluble C3 rapidly, generating more C3b that deposits on the surface and recruits more Factor B, creating an exponential amplification loop. A single C3bBb molecule can cleave hundreds of C3 molecules per minute.
5. Properdin stabilization — Properdin (Factor P) is the only positive regulator of the alternative pathway. It binds directly to C3bBb and extends the convertase half-life approximately tenfold (from ~90 seconds to ~15 minutes), dramatically amplifying local complement deposition. Properdin can also bind C3b directly and serve as a recruitment platform for Factor B.
6. Regulation — Factor H binds C3b and competes with Factor B for the same C3b surface, while simultaneously accelerating Bb dissociation (decay-accelerating activity) and serving as Factor I cofactor to proteolytically inactivate C3b to iC3b — directly opposing Factor B-mediated amplification.
Disease Links: Gain-of-Function CFB Mutations and C3 Glomerulopathy
While Factor H loss-of-function mutations drive alternative-pathway hyperactivation in atypical hemolytic uremic syndrome (aHUS), CFB gain-of-function (GOF) mutations achieve the same net result from the opposite direction: by making the C3bBb convertase more active or more stable, they tip the amplification–regulation balance toward uncontrolled C3 consumption and downstream tissue injury.
The most studied example is the K323E variant (lysine to glutamic acid at position 323 in the SP domain), which forms C3bBb convertases with prolonged half-life and enhanced C3 cleavage activity. Functional characterization shows that K323E Factor B retains full hemolytic activity but generates a convertase that behaves similarly to C3 nephritic factor (C3NeF) — the pathogenic autoantibody against C3bBb found in many C3 glomerulopathy patients. Critically, K323E Factor B can mimic C3NeF in functional hemolytic and convertase assays, which means patients with the genetic GOF variant can be misclassified as C3NeF-positive (autoimmune) when they actually have a primary genetic defect (Urban et al., 2018, Autoimmunity, PMID: 29308663).
C3 glomerulopathy (C3G) — encompassing dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) — is the primary renal disease associated with CFB GOF variants. The defining pathological feature is predominant C3 deposition in the glomerular mesangium and/or capillary walls on renal biopsy, with very limited immunoglobulin staining, reflecting primary fluid-phase complement activation rather than immune complex deposition. Approximately 25% of C3G patients carry rare variants in complement genes (C3 and CFB being the most common), while the remainder have acquired complement-regulating antibodies such as C3NeF. Distinguishing genetic from acquired C3G has direct therapeutic implications, since rituximab (B-cell depletion) is effective for the autoimmune C3NeF-positive subtype but not for genetically determined GOF variants.
Factor B as a Drug Target: Iptacopan and the Proximal Complement Blockade Rationale
Factor B's central position in the alternative pathway amplification loop makes it one of the most attractive pharmacological targets in the complement system. Inhibiting Factor B at the convertase-formation step blocks not only the alternative pathway de novo but also the amplification of classical- and lectin-pathway-initiated responses (since all three pathways converge on C3b, which can recruit Factor B). This "proximal" blockade also limits the downstream C3b opsonization that drives extravascular hemolysis — a mechanism that C5 inhibitors (eculizumab, ravulizumab) cannot address because they act downstream of C3.
Iptacopan (Fabhalta®), an oral small-molecule Factor B inhibitor (allosteric binding in the vWFA MIDAS pocket, preventing C3b interaction), became the first oral complement monotherapy approved for PNH in December 2023. In the APPLY-PNH (anti-C5-experienced, persistent anemia) and APPOINT-PNH (complement-inhibitor-naive) Phase 3 trials, iptacopan demonstrated robust improvements in hemoglobin and transfusion independence, including superiority to C5 inhibitor therapy for hemoglobin normalization — a finding attributed to its ability to prevent both intravascular hemolysis (via terminal pathway blockade) and extravascular hemolysis (via C3b opsonization prevention).
Danicopan, an oral Factor D inhibitor that acts one step upstream of Factor B (blocking the protease that activates it), has a complementary pharmacological profile. By preventing Factor D from cleaving Factor B, danicopan also suppresses C3bBb formation, but the upstream site of action confers a somewhat different effect on extravascular hemolysis. In the Phase 3 ALPHA trial, adding danicopan to ravulizumab or eculizumab in C5-inhibitor-treated PNH patients with clinically significant extravascular hemolysis produced an increase in hemoglobin of 2.44 g/dL versus placebo at week 12, with most patients achieving hemoglobin response (Lee et al., 2023, Lancet Haematology, PMID: 38030318). Danicopan was subsequently approved as add-on therapy for PNH in this extravascular-hemolysis-predominant population.
These two approvals — both targeting the same alternative-pathway amplification node via adjacent mechanisms — validate Factor B biology as a clinically actionable research focus.
How Factor B Compares to Its Pathway Analogs and Regulatory Partners
| Protein | Pathway | Role | Key Research Association |
|---|---|---|---|
| Factor B | Alternative | Convertase catalytic subunit (pro-enzyme form) | C3G (GOF variants), PNH/aHUS (drug target) |
| C2 | Classical / Lectin | Functional analog to Factor B; forms C4b2a C3 convertase | Classical pathway amplification |
| Factor D | Alternative | Protease that activates Factor B within C3bB proconvertase | Upstream drug target; danicopan |
| Properdin | Alternative | Positive regulator; stabilizes C3bBb 10-fold | Convertase amplification; research tool |
| Factor H | Alternative | Decay-accelerating + Factor I cofactor; opposes Factor B | AMD (Y402H), aHUS (C-terminal mutations) |
| MASP-2 | Lectin | Functional analog to Factor D in lectin pathway; cleaves C2 | Lectin pathway activation |
Research Methods for Studying Factor B
- •Hemolytic activity assays — rabbit erythrocyte or sheep erythrocyte lysis assays in normal human serum or Factor-B-depleted serum reconstituted with wild-type or variant recombinant Factor B. The gold-standard functional readout for CFB GOF/LOF characterization.
- •C3 convertase stability assays — measuring the half-life of C3bBb (typically ~90 seconds) after assembly with purified components, with and without properdin or Factor H, in the presence of WT or variant Factor B. GOF variants like K323E show measurably extended half-lives in these assays.
- •Surface plasmon resonance (SPR) and bio-layer interferometry (BLI) — used to measure binding kinetics between Factor B and C3b (for affinity and K_D determination), between Factor B variants and Factor D, or between inhibitor compounds and the Factor B vWFA domain. See the site's SPR and BLI methodology guides.
- •Recombinant Factor B and Bb fragment expression — N-terminal (Ba) and C-terminal (Bb) fragments are routinely expressed in HEK293 or CHO systems for structural and binding studies; bacterial expression typically fails because of required glycosylation and disulfide bonds.
- •Ba/Bb generation assays — SDS-PAGE or Western blot-based monitoring of Factor B cleavage by Factor D in the presence of C3b, used to confirm that an inhibitor compound prevents the critical cleavage step without interfering with C3b binding.
- •CFB genotyping — next-generation sequencing or targeted amplicon panels covering the GOF hotspot residues in the SP domain are standard in C3G diagnostic genetic workup, always interpreted alongside Factor H (CFH) and C3 (C3) sequencing.
Common Pitfalls in Factor B Research
- •Mg²⁺ dependence. Factor B–C3b interaction is absolutely dependent on Mg²⁺ (coordinated at the MIDAS motif). EDTA-based buffers chelate Mg²⁺ and completely abolish Factor B proconvertase assembly — always use MgCl₂ in binding and activity assays and be cautious with common anticoagulants.
- •Confusing Factor D specificity for free vs. C3b-bound Factor B. Factor D has extremely restricted substrate specificity: it cleaves Factor B efficiently only when Factor B is bound to C3b in the proconvertase complex, not in solution. Mixing purified Factor D and Factor B in the absence of C3b produces no measurable cleavage — a common assay design mistake.
- •GOF variant misclassification as C3NeF. As noted above, CFB K323E and similar GOF variants produce a biochemical phenotype indistinguishable from C3NeF autoantibody in functional hemolytic assays. Any C3G patient with apparent C3NeF positivity in a functional assay should be confirmed with genetic sequencing before assuming autoimmune etiology.
- •Plasma Factor B depletion by complement activation during sample handling. Serum or plasma samples from patients with active complement consumption (active C3G, aHUS flare, active PNH) may have markedly reduced Factor B levels due to ongoing convertase assembly and degradation — always collect samples in EDTA (though this disrupts Mg²⁺-dependent activity assays) and process rapidly.
Frequently Asked Questions
Is Factor B a peptide?
Factor B is a 93 kDa, 764-amino-acid plasma glycoprotein — a full-length serine protease precursor, not a peptide. It is included here because (a) short peptide fragments derived from the Ba and Bb regions are used as research tools and inhibitor-development scaffolds, (b) the vWFA-domain MIDAS pocket that binds Mg²⁺ involves peptide backbone contacts critical to complement function, and (c) the mechanistic biology and drug-target rationale inform complement-peptide research broadly.
How does Factor B relate to Factor H?
They are functional opposites targeting the same convertase from opposite angles: Factor B is the catalytic subunit that forms the C3bBb amplification complex, while Factor H disassembles it. The balance between Factor B assembly (promoted by properdin) and Factor H-mediated decay determines the level of alternative-pathway activity on any given surface. The full Complement Factor H profile covers the regulatory arm of this balance.
Why does iptacopan (Factor B inhibitor) suppress extravascular hemolysis when C5 inhibitors do not?
C5 inhibitors block terminal-pathway MAC formation and intravascular hemolysis but leave C3b opsonization intact — C3b continues to be deposited on PNH red cells, tagging them for clearance by spleen/liver macrophages (extravascular hemolysis). Factor B inhibition by iptacopan prevents the C3b amplification loop entirely, eliminating both C3b surface deposition and downstream MAC formation, resolving both hemolysis mechanisms simultaneously.
---
This article is for research and educational purposes only. It does not constitute medical advice, and none of the compounds, assays, or findings described are intended for human or animal therapeutic use outside of properly authorized clinical research.